UCB

BE BOLD: BIMZELX® (bimekizumab-bkzx) builds on superior joint responses versus SKYRIZI® (risankizumab-rzaa) at Week 16, with clinical improvements sustained through Week 24

BIMZELX sustained numerically greater ACR50 responses through all timepoints: 54.9% receiving BIMZELX versus 43.8% receiving risankizumab achieved…